News & Resources
The record behind SurVaxM.
Peer-reviewed publications, trial data, press coverage and corporate materials, maintained here as the current reference for clinicians, partners and media.
In the news
Media coverage.
Press Releases
Company announcements.
Press Release
Read →
MimiVax and Roswell Park Announce Results from Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
Press Release
Read →
MimiVax Announces Data Cutoff for Phase 2b SURVIVE Trial of SurVaxM in Newly Diagnosed Glioblastoma
Press Release
Read →
MimiVax and Roswell Park Open Phase 2 Trial of SurVaxM for Patients with Metastatic Neuroendocrine Tumors
Press Release
Read →
MimiVax and UI Pharmaceuticals Achieve Milestone in SurVaxM Production for Glioblastoma Treatment
Press Release
Read →
US FDA Awards Supplemental Orphan Drug Designation to SurVaxM to Now Include Treatment of Malignant Glioma
Press Release
Read →
MimiVax Announces New Investments to Support Clinical Development of SurVaxM in Glioblastoma
Resources
Publications, coverage and company materials.
Data
Read →
Final data from the Phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma
Looking for trial data
The full pipeline has phase-by-phase status.
For where each program stands today, the Pipeline page is the fuller reference.